An Open-Label, Dose-escalation, Phase I Study to Determine the Maximum Tolerated Dose, Recommended Dose, Pharmacokinetics, and Pharmacodynamics of the Proteosome Inhibitor CEP 18770 Given Intravenously as Single Agent in Patients With Advanced Solid Tumours or Non-Hodgkin's Lymphomas
This Phase 1 escalating-dose study is designed to assess, the safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel proteasome inhibitor CEP 18770, given intravenously as single agent, in patients with advanced, incurable solid tumours or NHL, and to identify the recommended dose of CEP 18770 to be used in Phase 2 studies.
100 Clinical Results associated with ETHICAL ONCOLOGY SCIENCE S.P.A.
0 Patents (Medical) associated with ETHICAL ONCOLOGY SCIENCE S.P.A.
100 Deals associated with ETHICAL ONCOLOGY SCIENCE S.P.A.
100 Translational Medicine associated with ETHICAL ONCOLOGY SCIENCE S.P.A.